title: [Stage III NSCLC. The role of the chemotherapist].
abstract: Standard treatment for non resectable stage III non-small cell lung cancer consists of concurrent chemotherapy and thoracic radiotherapy. There is no standard chemotherapy regimen, and several cisplatin-based doublets can be used. Induction and consolidation chemotherapy have been shown to yield no survival benefit. Although maintenance gefitinib has no interest after concurrent chemoradiotherapy, there is a rational for the delivery of targeted therapies in combination with radiotherapy. Other strategies integrating targeted treatments and radiotherapy warrant investigations.
authors.affiliation: Université de Franche-Comté, Service de Pneumologie, CHU Hôpital Jean-Minjoz, Boulevard Fleming, Besançon, France. virginie.westeel@univ-fcomte.fr
authors.forename: V
authors.initials: V
authors.lastname: Westeel
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D009367:Neoplasm Staging